Retail Trade MatsukiyoCocokara & Co. Business Summary
MatsukiyoCocokara & Co. engages in the management and supervision of its group companies that are in drugstore and pharmacy operations. It operates through the following segments: Retail Business, Wholesale Business, and Management Support. The Retail Business segment deals with the retail sales of pharmaceutical and related products. The Wholesale Business segment operates as a wholesale distributor of medicines and miscellaneous daily goods, and offers franchising services. The Management Support segment manages the Group and indirect operations. The company was founded on October 1, 2007 and is headquartered in Matsudo, Japan.
Financial Highlights
Mar 2021
JPY USD Revenue 556,907M 5,250.99M Gross Profit 173,518M 1,636.07M Operating income 31,522M 297.21M Income before tax 32,617M 307.54M Net income 21,568M 203.36M EBITDA 40,100M 378.09M Diluted EPS 210.03 1.98 Dividends Per Share 70 0.66 Total Assets 368,924M 3,338.67M Total liabilities 122,458M 1,108.21M Total equity 246,461M 2,230.41M Operating cash flow 25,875M 243.97M Currency in JPY Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
535,133M
558,879M
575,991M
590,593M
556,907M
Gross Profit
150,340M
161,502M
171,249M
181,036M
173,518M
Operating income
28,431M
33,567M
36,029M
37,554M
31,522M
Income before tax
28,815M
34,418M
37,369M
39,078M
32,617M
Net income
20,119M
22,755M
25,035M
26,176M
21,568M
EBITDA
36,376M
41,271M
44,262M
45,957M
40,100M
Diluted EPS
188.97
214.92
239.32
254.93
210.03
Dividends Per Share
47.50
55
65
70
70
Total Assets
285,733M
314,178M
318,324M
351,809M
368,924M
Total liabilities
101,670M
109,303M
109,050M
122,499M
122,458M
Total equity
184,060M
204,871M
209,269M
229,304M
246,461M
Operating cash flow
23,719M
27,938M
21,897M
24,764M
25,875M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
4,941.77M
5,042.55M
5,194.03M
5,431.95M
5,250.99M
Gross Profit
1,388.34M
1,457.17M
1,544.24M
1,665.06M
1,636.07M
Operating income
262.55M
302.86M
324.89M
345.40M
297.21M
Income before tax
266.09M
310.54M
336.97M
359.41M
307.54M
Net income
185.79M
205.30M
225.75M
240.75M
203.36M
EBITDA
335.92M
372.37M
399.13M
422.68M
378.09M
Diluted EPS
1.74
1.93
2.15
2.34
1.98
Dividends Per Share
0.43
0.49
0.58
0.64
0.66
Total Assets
2,564.23M
2,954.18M
2,875.94M
3,258.84M
3,338.67M
Total liabilities
912.41M
1,027.76M
985.22M
1,134.72M
1,108.21M
Total equity
1,651.79M
1,926.38M
1,890.67M
2,124.07M
2,230.41M
Operating cash flow
219.03M
252.07M
197.45M
227.76M
243.97M
Valuation Measures
Mar 2021
PER 23.46 ROA 5.98% ROE 9.06% Operating margin 5.66% Profit margin 3.87%
Key executives
President & Representative Director:
Kiyoo Matsumoto
Manager-Finance & Accounting:
Hiroshi Nishida
Senior Manager-Information System:
Hidesato Hiramatsu
Representative Director & Vice President:
Atsushi Tsukamoto
Executive Officer & Head-Kyushu Sales:
Takao Watanabe Shareholders
MATSUMOTO NAMIO (5.0%)
The Chiba Bank, Ltd. (3.5%)
Nomura Asset Management Co., Ltd. (3.2%)
Columbia Management Investment Advisers LLC (2.4%)
The Vanguard Group, Inc. (2.0%)
Eisai Co., Ltd. (1.9%)
MATSUMOTO TAKASHI /MATSUMOTOKIYOSHI/ (1.7%)
MATSUMOTO KIYOO (1.7%)
T. Rowe Price International Ltd. (1.4%)
Templeton Investment Counsel LLC (1.4%)
Related Companies
Matsumotokiyoshi Insurance Service Co., Ltd.
Matsumotokiyoshi Wholesale Co., Ltd.
Matsumotokiyoshi Pharmacies Co., Ltd.
Matsumotokiyoshi Kyushu Sales Co., Ltd.
Matsumotokiyoshi Hd Restricted Stock Compensation Plan
Matsumotokiyoshi Holdings Employee Incentive Plan
Matsumotokiyoshi Holdings Board Incentive Plan
Daruma Drug Co., Ltd.
Matsumotokiyoshi Kou-Shin-Etsu Japan Co., Ltd.
Yukari Kokoku KK
MK Higashinihon Hambai KK
Tobu Drug KK
MK Planning KK
Moris Retail KK
Koyo Yakuhin Co., Ltd.
Sugiura Co., Ltd.
Itayama Medico Co. Ltd.
Nakajima Family Yakkyoku KK
Shimeno Yakkyoku KK
Matsumotokiyoshi Asset Management Co., Ltd.
cocokara fine Inc.
Love Drugs Co., Ltd.
Matsumotokiyoshi Co., Ltd.
Midoriyakuhin Co., Ltd.
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 16 May, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close